Editorial: Engineered Targeted Cancer Immunotherapies

Editorial: Engineered Targeted Cancer Immunotherapies

Bibliographic Details
Main Authors:	Massimo Fantini, Roberto Bei
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Series:	Frontiers in Oncology
Subjects:	cancer immunotherapy monoclonal antibodies CAR-T cells CAR-NK cells antibody-dependent cell-mediated cytotoxicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.953175/full

Similar Items

Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar
by: Bella Guerrouahen, et al.
Published: (2021-01-01)

Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy
by: Massimo Fantini, et al.
Published: (2023-11-01)

NK Cell-Based Immunotherapy in Colorectal Cancer
by: Mariella Della Chiesa, et al.
Published: (2022-06-01)

Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?
by: Roberto Ruiu, et al.
Published: (2022-04-01)

2020 FDA/EMA approvals for new immunotherapy drug technologies and applications
by: Maryam Monajati, et al.
Published: (2021-06-01)

Emerging Targeted Therapies for HER2-Positive Breast Cancer
by: María Florencia Mercogliano, et al.
Published: (2023-03-01)

Emerging Trends in Immunotherapy for Cancer
by: Alok K. Mishra, et al.
Published: (2022-09-01)

Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights
by: Zuhui Pu, et al.
Published: (2023-11-01)

Natural killer cells: a promising immunotherapy for cancer
by: Junfeng Chu, et al.
Published: (2022-05-01)

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies
by: Vitaly Chasov, et al.
Published: (2024-02-01)

Generating Anti-TIGIT and CD155 Monoclonal Antibodies for Tumor Immunotherapy
by: Yu-Hang Duan, et al.
Published: (2022-09-01)

Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers
by: Mukulika Bose, et al.
Published: (2020-11-01)

CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
by: Ler Yie Chan, et al.
Published: (2022-03-01)

Immunotherapeutic Strategies for Neuroblastoma: Present, Past and Future
by: Fabio Morandi, et al.
Published: (2021-01-01)

Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
by: Massimo Giuliani, et al.
Published: (2020-06-01)

The Evolution of Cancer Immunotherapy
by: Meshaal Khan, et al.
Published: (2021-06-01)

Cancer Immunotherapy: Where Next?
by: Walter Bodmer, et al.
Published: (2023-04-01)

The prospect of genetically engineering natural killer cells for cancer immunotherapy
by: Angie Yu Ching Poon, et al.
Published: (2022-12-01)

Editorial: New insights into innate immune cell-based immunotherapies in cancer
by: Anne Caignard, et al.
Published: (2024-04-01)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
by: Sergey Kulemzin, et al.
Published: (2021-11-01)

Mechanisms of Resistance to NK Cell Immunotherapy
by: Christian Sordo-Bahamonde, et al.
Published: (2020-04-01)

New Orders to an Old Soldier: Optimizing NK Cells for Adoptive Immunotherapy in Hematology
by: Mehmet Gunduz, et al.
Published: (2021-09-01)

The Role of Monoclonal Antibodies in the Era of Bi-Specifics Antibodies and CAR T Cell Therapy in Multiple Myeloma
by: Meera Mohan, et al.
Published: (2021-09-01)

Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
by: Xinyu Wu, et al.
Published: (2022-12-01)

NK cell mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
by: Wei eWang, et al.
Published: (2015-07-01)

Engineered Microphysiological Systems for Testing Effectiveness of Cell-Based Cancer Immunotherapies
by: Marco Campisi, et al.
Published: (2022-07-01)

Non‐coding RNAs in cancer immunotherapy: Predictive biomarkers and targets
by: Murad Alahdal, et al.
Published: (2023-09-01)

Outsmarting trogocytosis to boost CAR NK/T cell therapy
by: Faezeh Ramezani, et al.
Published: (2023-11-01)

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy
by: Gemma Ferrer-Curriu, et al.
Published: (2023-02-01)

Recent Advances in CAR-Based Solid Tumor Immunotherapy
by: Min Hwa Shin, et al.
Published: (2023-06-01)

Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives
by: Nora Berois, et al.
Published: (2022-01-01)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
by: Kevin Pan, et al.
Published: (2022-03-01)

The role of MSCs and CAR-MSCs in cellular immunotherapy
by: Lun Yan, et al.
Published: (2023-08-01)

Harnessing natural killer cells to develop next‐generation cellular immunotherapy
by: Siyao Liu, et al.
Published: (2022-12-01)

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer
by: Ke-Tao Jin, et al.
Published: (2021-02-01)

CD19-Targeted Immunotherapies for Diffuse Large B-Cell Lymphoma
by: Massimiliano Gambella, et al.
Published: (2022-02-01)

Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
by: Sabarinath Venniyil Radhakrishnan, et al.
Published: (2017-05-01)

Immune evader cancer stem cells direct the perspective approaches to cancer immunotherapy
by: Hassan Dianat-Moghadam, et al.
Published: (2022-04-01)

DNAM-1 chimeric receptor-engineered NK cells: a new frontier for CAR-NK cell-based immunotherapy
by: Loredana Cifaldi, et al.
Published: (2023-06-01)

GD2-targeting therapy: a comparative analysis of approaches and promising directions
by: Julia Philippova, et al.
Published: (2024-03-01)